GSK Obtains Exclusive Rights to Amicus Therapeutics’ Drug for Fabry Disease

By Editorial Team

Pharma Deals Review: Vol 2010 Issue 9 (Table of Contents)

Published: 30 Nov-2010

DOI: 10.3833/pdr.v2010.i9.1400     ISSN: 1756-7874

Section: Licensing



GlaxoSmithKline has licenced Amigal™, a late stage treatment for the rare disorder Fabry disease...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details